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Advancing age is a well-known risk factor for tendon disease. Energy storing tendons, (e.g. 2 
human Achilles, equine superficial digital flexor tendon (SDFT)) are particularly vulnerable 3 
and it is thought that injury occurs following an accumulation of micro-damage in the 4 
extracellular matrix (ECM). Several authors suggest that age-related micro-damage 5 
accumulates due to a failure of the aging cell population to maintain the ECM or an 6 
imbalance between anabolic and catabolic pathways. We hypothesised that ageing results in a 7 
decreased ability of tendon cells to synthesise matrix components and matrix degrading 8 
enzymes, resulting in a reduced turnover of the ECM and a decreased ability to repair micro-9 
damage. The SDFT was collected from horses aged 3-30 years with no signs of tendon 10 
injury. Cell synthetic and degradative ability was assessed at the mRNA and protein levels. 11 
Telomere length was measured as an additional marker of cell ageing. There was no decrease 12 
in cellularity or relative telomere length with increasing age, and no decline in mRNA or 13 
protein levels for matrix proteins or degradative enzymes. The results suggest that the 14 
mechanism for age-related tendon deterioration is not due to reduced cellularity or a loss of 15 
synthetic functionality and that alternative mechanisms should be considered.  16 
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Ageing results in a gradual and inevitable decline in the performance of physiological 2 
systems in the body. Changes to the musculoskeletal system are easily observed as 3 
individuals lose their strength and flexibility and athletic performance declines. Furthermore, 4 
susceptibility to skeletal tissue injury increases with advancing chronological age. Several 5 
epidemiological studies have shown a marked increase in the incidence of tendon and 6 
ligament injuries in older age groups, beyond the age of peak athletic ability (Clayton and 7 
Court-Brown, 2008; Hess, 2010; Raikin et al., 2013). For example, in the patellar tendon the 8 
peak in incidence of injury occurs in the seventh decade of life  and the incidence of Achilles 9 
tendon injury peaks in middle age (40-60 years) (de Jonge et al., 2011), with a smaller peak 10 
in women in their seventh decade (Clayton and Court-Brown, 2008). These studies suggest 11 
there is an age related decline in tendon health rather than simple mechanical overload. 12 
Tendon injuries are also prevalent in horses; most injuries occur to the superficial digital 13 
flexor tendon (SDFT) (Ely et al., 2009). Injuries to the SDFT are remarkably similar to those 14 
seen in the human Achilles tendon, both in terms of risk factors and the pathology. It is well 15 
documented that older horses are at a higher risk of SDFT injury than younger horses (Avella 16 
et al., 2009; Ely et al., 2009; Williams et al., 2001). The equine SDFT and human Achilles 17 
tendon have a spring-like function, storing and releasing elastic strain energy (Lichtwark and 18 
Wilson, 2005; Wilson et al., 2001). Tendons with this specialised function appear to be 19 
particularly prone to age-related pathologies. 20 
The equine SDFT and human Achilles tendon, in their energy storing roles, are subjected to 21 
high strains. These tendons therefore require mechanical properties that allow them to 22 
withstand repeated cycles of loading and unloading at strains of up to 16% and 11% 23 
respectively (Lichtwark and Wilson, 2005; Stephens et al., 1989). These properties are 24 
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provided by a complex hierarchical arrangement of collagen molecules interspersed with 1 
non-collagenous components throughout the matrix such as proteoglycans and glycoproteins 2 
(see Thorpe et al., 2013 for review). The fibril forming type I collagen forms about 75% of 3 
the dry weight of tendon (Birch et al., 2008a). A relatively sparse population of tendon cells 4 
or tenocytes maintains this large amount of load-bearing collagenous matrix and the 5 
supporting non-collagenous extracellular matrix. 6 
While tendon ruptures can occur due to an acute overloading event, or laceration, tendon 7 
injuries are often accompanied by evidence of chronic degeneration (Thomopoulos et al., 8 
2015), suggesting that damage has been accumulating within the tendon. This accumulation 9 
of microdamage is thought to result in a gradual weakening of the hierarchical structure, but 10 
the nature of this micro-damage and the pathways by which it forms are not clear. Several 11 
authors however suggest a failure of the cell population to maintain the extracellular matrix 12 
or an imbalance between anabolic and catabolic pathways favouring matrix degradation 13 
(Riley, 2008). The degradation of the matrix occurs through the combined action of members 14 
of the matrix metalloproteinase (MMP) and A Disintegrin And Metalloproteinase with 15 
ThromboSpondin motif (ADAMTS) family. Only the secreted collagenases (MMP-1 and 16 
MMP-13) are able to cleave the intact collagen triple helix away from the cell surface, 17 
however once cleaved, the denatured collagen molecule can then be degraded by other 18 
proteases.  19 
Early observations in ageing research established that both protein synthesis and degradation 20 
decline during ageing (Tavernarakis, 2008) resulting in a limited capacity of the cellular 21 
maintenance, repair and turnover pathways and possible accumulation of age related damage. 22 
In keeping with this, our research has shown that, although cell density does not decline 23 
(Birch et al., 1999), collagen half-life, calculated by measuring D and L forms of aspartate in 24 
an injury prone tendon, increases with increasing age (Thorpe et al., 2010), suggesting a 25 
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decline in the ability of the tendon cells (tenocytes) to synthesise new matrix components. In 1 
a more recent study, we have used proteomic analysis to show that levels of some matrix 2 
components, including several proteoglycans, decrease with ageing (Peffers et al., 2014). The 3 
results of our previous work also suggest a reduced ability of the tenocytes to degrade the 4 
matrix components, as the levels of type I collagen crosslinked telopeptide (ICTP), a marker 5 
of mature collagen degradation, decline with increasing age (Thorpe et al., 2010). Our 6 
previous work was not able to determine whether reduced collagen turnover results from a 7 
failure of the tendon cell population to synthesise high levels of MMPs or whether changes in 8 
the matrix render it less digestible. The aim of the current study was therefore to assess 9 
changes in cell metabolism and the balance between anabolic and catabolic potential with 10 
advancing age. 11 
We hypothesised that ageing results in a decreased ability of tendon cells to synthesise matrix 12 
components and matrix degrading enzymes, resulting in a reduced turnover of the 13 
extracellular matrix. We have used the equine SDFT for our studies as this tendon is injury 14 
prone and shows a clear age related increase in susceptibility to damage. We have collected 15 
tendons from a wide age range of horses and investigated in situ cell synthetic ability by 16 
assessing expression of matrix proteins at mRNA and protein level and the ability to degrade 17 
the matrix by measuring expression of matrix degrading enzymes and enzyme activity. In 18 
addition, relative telomere length was measured as a marker of ageing based on cellular 19 
growth and proliferation rather then extracellular matrix synthesis.  20 
Materials and Methods 21 
Sample Collection 22 
The right forelimbs of skeletally mature horses with a wide age range (n = 32, age range 3 to 23 
30 years) euthanased for reasons other than tendon injury were collected from a commercial 24 
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abattoir. Horses above the age of 20 years are considered to be geriatric (Brosnahan and 1 
Paradis, 2003). The SDFT was dissected free from the limbs at the level of the 2 
metacarpophalangeal joint and examined for macroscopic signs of injury. Only tendons with 3 
no signs of injury were included in the study. Tissue was harvested from the mid-metacarpal 4 
region of each SDFT. For DNA and protein analysis, samples were snap frozen in hexane 5 
cooled on dry ice and stored at -80 ºC prior to processing. When required, snap-frozen tendon 6 
samples were thawed and the periphery of the tendon removed. Samples were lyophilised at -7 
40 ºC until a constant weight was reached, then reduced to a fine powder using a micro-8 
dismembrator (Sartorius, Germany) at 3000 rpm for 2 minutes, and stored at -80 ºC prior to 9 
analysis. Samples for RT-qPCR were stored in RNAlater at 4 °C for 24 hours, before being 10 
stored at -20 °C until required for analysis.  11 
Tendon DNA Content 12 
Lyophilised samples were accurately weighed and papain digested according to Birch et al. 13 
(1998). Immediately after papain digestion the DNA content of the tendons was measured 14 
using the bisbenzimidazole dye Hoechst 33258, according to Kim et al. (1988) and expressed 15 
as μg per mg dry weight tendon tissue. 16 
RT-qPCR 17 
Tissue samples stored in RNAlater (Ambion) were chopped and pulverised for 2 min. at 2000 18 
oscillations/minute in a liquid nitrogen cooled dismembranator (Braun Mikro-Dismembrator 19 
Vessel, Braun Biotech International, Melsungen, Germany). RNA was extracted using a 20 
phenol-chloroform extraction (TriReagent™, Sigma) followed by purification using a 21 
commercially available kit (RNeasy Mini Kit, Qiagen), including an on-column DNA 22 
digestion step (RNase-Free DNase Set, Qiagen). RNA was stored at -80°C prior to reverse 23 
transcription. RNA concentration was measured (ND-1000 spectrophotometer Nanodrop 24 
Technologies) and 1 μg RNA was used to prepare 20μl cDNA using M-MLV reverse 25 
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transcriptase and random primers according to the manufacturer's instructions (Promega). 1 
Samples were stored at -20°C prior to relative quantification of gene expression. Primers 2 
were designed using Primer Express (Applied Biosystems) software and selected to span 3 
predicted exon boundaries where possible. BLAST searches were performed for all 4 
sequences to confirm gene specificity. Target and reference gene primers were synthesized 5 
by Eurogentec. Specificity and efficiency between 95 - 105 % was confirmed for all primers 6 
(Taylor et al., 2009). GeNorm (Vandesompele et al., 2002) identified HIRA-interacting 7 
protein 5 (HIRP-5) and mitochondrial ribosomal protein S7 (MRPS-7) as the two most stably 8 
expressed genes from a panel of 8 candidate reference genes. All data were therefore 9 
normalised to the average expression of HIRP-5 and MRPS-7 using the 2-ΔCt method (Livak 10 
and Schmittgen, 2001). RT-qPCR assays were performed in triplicate using the 7900 HT Fast 11 
Real-Time PCR System (Applied Biosystems; Warrington, UK) in 384 well plates. Reaction 12 
volume in each well was 10 μl (4.6 μl cDNA, 5 μl Power SYBR mastermix (Applied 13 
Biosystems), 0.1 μl DEPC water, 0.15 μl 3 μM forward primer and 0.15 μl 3 μM reverse 14 
primer). The cycling conditions comprised 10 min polymerase activation at 95°C and 40 15 
cycles at 95°C for 15 sec and 60°C for 60 sec. Data were then analysed using Sequence 16 
Detection Systems Software v2.2.1 (Applied Biosystems; Warrington, UK).   17 
Western Blotting for PINP 18 
Collagen synthesis was assessed at the protein level in the SDFT from 14 horses selected 19 
from the sample group based on age range (6 – 30 years). Pro-collagen was detected using an 20 
antibody for the N-terminal propeptide of type-I collagen (PINP) using Western blotting; this 21 
antibody (SP1.D8, Developmental Studies Hybridoma Bank, The University of Iowa, 22 
Department of Biological Sciences, Iowa, UK) has been previously shown to cross react with 23 
the horse (Young et al., 2009).  24 
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PINP was extracted from the tendon matrix using Guanidine-HCl (GndHCl) extraction 1 
followed by precipitation according to Birch et al. (2008b). The remaining pellet was 2 
reconstituted in 100 µl 2x reducing buffer (10% mecaptoethanol in 125 mM Tris, 2% SDS, 3 
10% glycerol, pH 6.8) and heated at 60 ºC for 5 min. before loading 20 µl of each sample 4 
onto the gels. Proteins were separated by SDS-PAGE on a 5 % acrylamide gel; a molecular 5 
weight standard (10 µl; Precision Plus Standards, Biorad Laboratories Ltd., Hemel 6 
Hempstead, UK) was run alongside the samples on each gel. Proteins were separated by 7 
applying a constant current of 20 mA per gel to the gels for 55 min. 8 
After electrophoresis, proteins were transferred to PVDF membranes (Amersham Hybond-P, 9 
GE Healthcare, Amersham, UK) by blotting for 75 min at 100 V. After washing, membranes 10 
were probed with the PINP primary antibody (SP1.D8, diluted 1 in 1000 in TBS-Tween) for 11 
2 hours at room temperature, followed by incubation with an enhanced chemi-luminescent 12 
(ECL) peroxidase labelled anti-mouse secondary antibody (GE Healthcare, diluted 1 in 10 13 
000 in TBS-T). Blots were developed with Amersham ECL Plus™ Western blotting 14 
detection reagents (GE Healthcare) according to the manufacturer’s instructions, with an x-15 
ray exposure time of 10 min. Resulting x-ray films were photographed on a lightbox (Nikon 16 
Coolpix, 5700) and band areas corresponding to 2 chain with PINP and PICP (Fig. S1) were 17 
quantified using Scion Image (Version 4.0.3.2, Scion Corporation, Maryland, USA). 18 
Fluorescent Substrate Assay (MMP-13) 19 
A fluorogenic assay was used to assess protein levels of latent and active forms of MMP-13 20 
in the SDFT according to Birch et al. (2008b).  Briefly, lyophilised tendon tissue was 21 
suspended in extraction buffer (50 mM HEPES, 200 mM NaCl, 1 mM CaCl2, 0.01% BRIJ-22 
35, pH 7.3) and incubated at 22 °C for 60 min. Samples were centrifuged (16 000 g, 5 min.) 23 
and the supernatant was removed and stored at -80 °C. Aliquots of supernatant were pipetted 24 
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into a 96 well fluorometer plate in duplicate. Fluorescence was measured in the presence and 1 
absence of amino-phenyl mercuric acetate to determine the amount of latent active MMP-13 2 
in the samples. A quenched fluorescence substrate for MMP-13 (Calbiochem) was added to 3 
each well to give a final concentration of 0.1 mM. Plates were incubated at 37 °C and 4 
fluorescence measured after 2 h on a fluorescence reader (Bio-tek Instruments Inc. FLX800 5 
microplate reader) with excitation and emission wavelengths of 325 nm and 393 nm 6 
respectively. Activity was expressed as relative fluorescence units per mg tissue. 7 
Gelatin and Casein Zymography 8 
Lyophilised tendon tissue was incubated in 2x non-reducing sample buffer (approximately 15 9 
mg tissue in 600 µl; 125 mM Tris, 2% SDS, 10% glycerol, 0.01% bromophenol blue at pH 10 
6.8) at 22 ˚C for 30 min. The samples were centrifuged (16 000 g, 2 min.) and the supernatant 11 
was removed and stored at -80 °C. Samples were separated on 8 % acrylamide gels 12 
containing bovine gelatin type B (1 mg/ml), and 10 % gels containing β-casein (1 mg/ml). A 13 
molecular weight marker and an MMP-9 standard prepared from equine neutrophil cells were 14 
included on each gel (see supplementary information). 15 
After electrophoresis, gels were washed in 2.5% Triton X-100 solution for 1 hour, rinsed in 16 
incubation buffer (50 mM Tris, 0.2% Sodium Azide, 5 mM Calcium chloride, pH 7.6) and 17 
then incubated in incubation buffer (as above) at 37 °C for 40 hours. Gels were then rinsed 18 
and stained for 30 min in Coomassie Blue (0.5% Coomassie Blue R250, 30% methanol, 10% 19 
acetic acid). After staining, the gels were de-stained (10% methanol, 5% acetic acid) for 20 20 
hours. Gels were photographed (Nikon Coolpix, 5700) and analysed using Scions β 4.0.2 21 
image analysis software (Scion Corporation, Maryland, USA). For gelatin zymography, 22 
digestion bands were expressed per mg of tissue and relative to the MMP-9 standard. For 23 
casein zymography, an SDFT sample with a relatively high concentration of MMP-3 was 24 
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identified and run on every gel, and the activity of MMP-3 in all other samples were 1 
expressed relative to this sample.  2 
Telomere Length Measurements 3 
Genomic DNA was extracted from the SDFT of 32 horses using the DNeasy Blood and 4 
Tissue Kit (Qiagen) according to manufacturer’s instructions for the purification of total 5 
DNA from animal tissues. Relative telomere lengths were then determined using the 6 
singleplex qPCR method described in detail by Cawthon (2002). One SDFT DNA sample 7 
served as a reference sample and was serially diluted by three-fold per dilution to give five 8 
DNA concentrations ranging from 0.185 to 15 ng/µl, which were then added to the standard 9 
curve wells of a 96-well PCR plate in 10 µl aliquots. For all other samples, 16.7 ng DNA 10 
(middle of the standard curve range) was added to each sample well in triplicate. Separate 11 
master mixes were prepared for the telomere (T) and single copy gene (S) primer pairs (3 12 
µM) using the GoTaq qPCR SYBR green master mix (Promega) and each sample was 13 
assayed for each primer pair separately. The vertebrate telomere primer sequences were (5’ to 14 
3’): Tel1, GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT; Tel2, 15 
TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA; and the single copy gene 16 
(equine GAPDH) primer sequences were: forward, GCATCGTGGAGGGACTCA; reverse, 17 
GCCACATCTTCCCAGAGG. All PCR was performed on an Applied Biosystems 7300 18 
instrument.  19 
For the standard curves, the average Ct values for each DNA standard were plotted for both 20 
the T and S primer pairs. The linear regression equations produced for each primer pair was 21 
then used to generate the T and S values for each of the SDFT samples using the average 22 
SDFT Ct values. The T/S ratio, for each SDFT sample was then determined to give a relative 23 
measure of telomere length.  24 
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Statistical Analysis 1 
Data were tested for normality using Kolmongorov-Smirnov analysis (Minitab, version 15). 2 
Correlation was assessed using Pearson Product Moment Correlation for parametric data and 3 
Spearman’s rank correlation for non-parametric data (SPSS, version 14). Statistical 4 
significance was set at p<0.05. All data are displayed as mean ± SEM. 5 
Results 6 
Cell number does not decline with increasing age  7 
To give an indication of tendon tissue cellularity and any change in cell concentration with 8 
increasing horse age, the amount of DNA was assayed in papain-digested samples of tendon 9 
tissue. Our results show DNA levels of 0.54 ± 0.02 g/mg (mean ± SEM) and no significant 10 
change in DNA levels with ageing in the equine SDFT (Fig. 1).  11 
Expression of matrix proteins in relation to donor age 12 
To assess the potential for matrix synthesis, we quantified levels of mRNA for some of the 13 
main protein components of the extracellular matrix in tendon tissue. These included the 2 14 
chain of type I collagen, 1 chain of type III collagen, 1 chain of type V collagen, 1 chain 15 
of type XII collagen, decorin, biglycan, fibromodulin,  lumican, aggrecan and collagen 16 
oligomeric matrix protein (COMP).  In addition, we measured expression of scleraxis and 17 
tenascin, two genes coding for proteins considered to be markers of a tenogenic phenotype 18 
(Jelinsky et al., 2010). Expression of all genes was detected (Table 1) however none of the 19 
mRNA transcript levels correlated with horse age (Table 1 & Fig. 2).  20 
Evidence for the synthesis of new collagen at the protein level was assessed by measuring 21 
levels of the N-terminal propeptide of type I collagen (PINP) in tissue extracts using Western 22 
blotting. Four bands were visible on the blot ranging from approximately 200 kDa to 155 kDa 23 
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molecular weight representing the 1 chain with PINP and C-terminal propeptide (PICP) 1 
attached, 2 chain with PINP and PICP, 1 chain with PINP and 2 chain with PINP (see 2 
supplementary information Figure S1). The 2 chain with PINP and PICP gave the clearest 3 
band in the majority of samples and so the area of this band was used for relative 4 
quantification of PINP levels between samples. The level of pro-collagen varied widely 5 
between individual horses and was not detectable in some samples, however levels did not 6 
relate to horse age (Fig. 3a). There was no relationship between the level of pro-collagen 7 
extracted from the tissue and the expression of Col1A2 at the mRNA level (Fig. 3b).  8 
Expression of matrix degrading enzymes in relation to donor age 9 
Expression of matrix degrading enzymes was measured at the mRNA level for the following 10 
enzymes; collagenases (MMP-1, MMP-13), stromelysins (MMP-3, MMP-10), gelatinases 11 
(MMP-2, MMP-9), MMP-23, ADAM-12, ADAM-17, and ADAMTS-2. In addition, the 12 
expression of tissue inhibitor of metalloproteinases (TIMP-3 and TIMP-4) was measured. 13 
Expression of all proteolytic enzymes and TIMPs was detected (Table 2) however none of the 14 
mRNA transcript levels correlated with horse age (Table 2 & Fig. 4) except for MMP-10 15 
expression, which increased significantly with increasing horse age (p=0.005). While not 16 
significant, there was a trend for increased MMP-3 expression with increasing age (p=0.054). 17 
Latent and active forms of matrix degrading enzymes at the protein level were quantified 18 
using a fluorogenic assay (MMP-13), gelatin zymography (MMP-2 and MMP-9) and casein 19 
zymography (MMP-3). MMP-13 was detected only in the active form (45.46 ± 5.66 RFU/mg 20 
tissue) and levels did not correlate with horse age. The gelatinases, MMP-2 and MMP-9, 21 
were detected in all tendon samples. MMP-9 was present entirely in the active form whereas 22 
MMP-2 was detected mainly in the latent form although small amounts of the active form 23 
were also present in most tendon samples (see supplementary information Figure S2). Neither 24 
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MMP-2 nor MMP-9 correlated with horse age and there was no correlation between MMP-9 1 
mRNA and protein levels. Casein zymography showed that MMP-3 was present mainly in 2 
the latent form (Pro MMP-3) with small amounts of active enzyme present in some tendon 3 
samples. Both pro MMP-3 and active MMP-3 levels increased significantly with increasing 4 
horse age (Fig. 5a). Total MMP-3 levels showed a weak but significant positive correlation 5 
with MMP-3 mRNA levels (Fig. 5b). 6 
Relative telomere length 7 
Relative telomere length was determined in DNA extracted from tendon tissue samples using 8 
a quantitative PCR technique (Cawthon, 2002). The results showed that relative telomere 9 
length, expressed as T/S ratios, did not decrease significantly with increasing horse age (Fig. 10 
6).  11 
Discussion 12 
The results of our study do not support our hypothesis and unexpectedly show that synthesis 13 
of matrix proteins and matrix proteases in the SDFT does not decline with increasing horse 14 
age. In a wide variety of other tissues and organisms, a decrease in protein synthesis is one of 15 
the most common age associated changes (Rattan, 1996) and has been linked to age-related 16 
neurodegenerative (Douglas and Dillin, 2010), cardiovascular, muscle and bone disease.  17 
Furthermore decline in the synthesis of matrix components has been shown in other skeletal 18 
tissues such as cartilage where it has been linked to osteoarthritis (Peffers et al., 2013). Our 19 
finding is therefore contrary to the widely accepted notion that decreased protein synthesis 20 
represents a universal phenomenon (Ryazanov and Nefsky, 2002).  21 
Tendon is characterised by a large amount of extracellular matrix, which is predominately 22 
protein and a relatively sparse population of cells. The tendon cells have the task of 23 
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maintaining proteostasis throughout life and in the face of mechanical challenges to the 1 
integrity of the matrix. One way this may be comprised is by declining cell numbers with 2 
increasing age. A number of previous studies have reported a decrease in cell number with 3 
increasing age in rat Achilles tendon (Yu et al., 2013), rat tail tendon (Lavagnino et al., 2013) 4 
and mice patellar tendons (Dunkman et al., 2013). However it is difficult to separate 5 
maturation and ageing effects in short lived species such as rats where growth plates remain 6 
open throughout life (Kilborn et al., 2002). Furthermore small mammals do not have tendons 7 
that are specialised for an energy storing role (Alexander, 2002), making extrapolations to 8 
age related deterioration to injury prone tendons in larger mammals difficult. The results of 9 
our study showed no decrease in DNA content with increasing horse age indicating that in an 10 
energy-storing tendon from a long-lived species decrease in cell number does not occur.  11 
In our study, we examined protein turnover by measuring synthesis at the transcriptional and 12 
translational levels and assessed the potential for degradation by measuring expression of 13 
matrix degrading enzymes. Proteostasis however involves additional regulatory steps of 14 
protein folding, processing, assembly, disassembly and localisation. Taking a more global 15 
view, we have previously shown, using aspartic acid racemisation, that the half-life of the 16 
collagenous component of the equine SDFT increases with increasing horse age suggesting a 17 
decrease in the rate of collagen synthesis (Thorpe et al., 2010). The results of the present 18 
study however demonstrate that the synthesis of collagen does not decline and suggest an 19 
alternative mechanism; that there is reduced ability to dissemble and reassemble the 20 
collagenous matrix. The first step in collagen degradation relies on the action of collagenases 21 
(MMP-1 and MMP-13) and we did not show reduced expression or activity of these 22 
enzymes. Interestingly, our previous work on the equine SDFT demonstrated an 23 
accumulation of the type I collagen neoepitope generated by collagenase activity in old tissue 24 
and reduced ability to extract partially degraded collagen from the tendon tissue (Thorpe et 25 
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al., 2010). Further, we have recently shown that overall protein extractability is reduced  with 1 
ageing in the SDFT (Peffers et al., 2014). Taken together with these previous findings, our 2 
results suggest that the ageing process results in modifications to matrix proteins rendering 3 
them resistant to turnover rather than reduced cellular capacity for matrix metabolism. 4 
Our previous work showed a distinction between collagenous and non-collagenous protein 5 
turnover and age related changes (Thorpe et al., 2010). The non-collagenous matrix had a 6 
lower half-life showing turnover is more rapid and in keeping with this, we find in this study 7 
that the levels of expression of non-collagenous proteins such as decorin, biglycan, lumican 8 
and COMP are higher than expression of collagens. Furthermore, this previous work found 9 
no age related decline in non-collagenous protein turnover and the data presented here show 10 
the levels of stromelysins responsible for proteoglycan degradation (MMP-3 and MMP-10) 11 
actually increase with increasing horse age. The differences observed between collagen and 12 
non-collagenous components may relate to the specialised role of the equine SDFT as an 13 
energy store and the mechanism by which specialised mechanical properties are attained. 14 
Recent work has demonstrated that high strains, which are essential for function in energy 15 
storing tendons, are achieved by sliding between fascicles and an inter-fascicular matrix with 16 
low stiffness (Thorpe et al., 2012). The majority of non-collagenous proteins reside in the 17 
inter-fascicular matrix and their important role in the mechanical function may necessitate a 18 
higher rate of turnover. 19 
It is of interest to note that although degeneration is associated with ageing, the results of this 20 
study highlight differences between the two processes. Gene expression studies on degenerate 21 
human Achilles tendon tissue found decreased expression of MMP-3 and MMP-10 in painful 22 
tendons and decreased expression of MMP-3 in the ruptured group (Jones et al., 2006). In 23 
another study, dysfunctional posterior tibialis tendons showed decreased expression of MMP-24 
3 (Corps et al., 2012), while our study showed that expression of both MMP-3 and MMP-10 25 
16 
 
increases with advancing age. Indeed previous analysis of degenerated equine SDFT (Birch 1 
et al., 1998), ruptured human supraspinatus tendon (Riley et al., 2002) and dysfunctional 2 
human posterior tibialis tendon (Corps et al., 2012) all demonstrated changes indicative of 3 
matrix remodelling, changes which this study suggests are not characteristic of ageing. 4 
Therefore while ageing may predispose to degeneration these appear to be two distinct 5 
processes. 6 
Although we interpret our data as demonstrating that ageing in tendon is a matrix 7 
phenomenon and not cell mediated, it may be that older cells are not able to respond to 8 
mechanical stimuli as efficiently as younger cells. It was not possible to obtain the exercise 9 
history of the horses used in this study, and as it is unlikely that any horse underwent high 10 
intensity exercise prior to euthanasia, the resident cells would have experienced low levels of 11 
stimuli. Therefore it is possible that aged cells may show a decreased response to loading. In 12 
addition, older cells may also show a reduced response to anabolic stimuli after injury. 13 
Following micro-trauma or gross injury an immediate inflammatory response is initiated 14 
(Dakin et al., 2012) and the release of a cascade of growth factors including IGF-1, TGF, 15 
PDGF, VEGF and bFGF follows, which stimulates the repair process (Molloy et al., 2003). 16 
Evidence from in vitro studies of chondrocytes (Loeser et al., 2000; Martin et al., 1997) and 17 
in vivo study of osteoblasts (Cao et al., 2007) suggests that cells in older individuals have a 18 
reduced capacity to respond to IGF-1. Recent work however has shown that local injection of 19 
IGF-1 into the patellar tendon of young and old men is able to stimulate protein synthesis to 20 
an equal degree demonstrating that the ability to respond to anabolic stimuli is maintained in 21 
older age (Nielsen et al., 2014). 22 
As we chose to focus on matrix proteins and matrix degrading proteins, our study would not 23 
detect other important age-related changes to tendon cell gene expression that may occur. A 24 
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previous study of ageing in cartilage, using Next Generation Sequencing to assess the full 1 
transcriptomic phenotype of chondrocytes, reported that 396 transcribed elements were 2 
differentially expressed with ageing, the majority of which were down-regulated in old 3 
samples (Peffers et al., 2013). Further, our recent work characterising the proteome of the 4 
SDFT from young and old individuals has shown that abundances of 34 proteins were altered 5 
with ageing, with decreased amounts of several proteoglycans, and increased cytoskeletal 6 
proteins in aged tendon (Peffers et al., 2014). While the abundance of major tendon matrix 7 
proteins were not altered with ageing, the change in amounts of some minor proteins may 8 
have important consequences for tendon health (Peffers et al., 2014). Future work should 9 
therefore attempt to characterise full transcriptomic signatures in tendon to further investigate 10 
tendon cell ageing, and relate this to changes seen at the protein level.   11 
Tendon is known to contain distinct populations of cells including a sub-population of 12 
progenitor cells (Bi et al., 2007). It is not known at present how these different cell 13 
populations contribute to tendon maintenance and anabolic response to injury. Recent work 14 
has shown that progenitor cells from aged/degenerate human Achilles tendon have reduced 15 
self-renewal and clonal capacity, leading to the proposal that reduced functional fitness of the 16 
stem cell pool is responsible for tendon degeneration (Kohler et al., 2013). While these 17 
findings may appear to contradict the results of our study, it is more likely that the studies are 18 
looking at different aspects. We assessed relative telomere length of the total cell population, 19 
whereas Kohler et al. (2013) studied ageing in a specific sub-population of tendon cells. The 20 
proportion of these progenitor cells relative to total tendon cell population is unclear, but it is 21 
likely that the majority of cells in tendon are a stable resident population of cells which are 22 
terminally differentiated, rather like osteocytes in bone tissue, hence telomere length does not 23 




Further, we choose to focus on healthy tendon over a range of ages with the intention of 1 
identifying age-related changes that may predispose to degeneration (micro-damage). Kohler 2 
et al. (2013) did not differentiate between cells from aged or degenerated tendons and it may 3 
be that the differences observed are due to degeneration rather than healthy ageing.  4 
In conclusion, the results of this study suggest that an important mechanism for age related 5 
tendon deterioration lies around protein post-translational modifications thereby disrupting 6 
the assembly and disassembly process of the functionally important collagenous scaffold and 7 
that future work should focus around understanding these processes. It is likely that similar 8 
processes occur in other collagen rich tissues with a relatively slow turnover. These matrix 9 
changes have implications for cell-based therapies, which aim to enhance synthetic 10 
capability, and suggest additional strategies must be adopted to tackle age related decline of 11 
skeletal tissues. As collagen is a ubiquitous and abundant protein, the results of this study are 12 
far reaching and findings in tendon are likely to translate to other skeletal tissues and 13 
connective tissue components of other organs where half-life is long, in addition to fibrotic 14 
tissue diseases.  15 
Perspectives 16 
While it is well established that the risk of tendon injury increases with ageing, the aetiology 17 
of this is unclear. In the current study, we have shown that there is no overall decline in 18 
tendon cell synthetic or degradative capacity with ageing, suggesting that other mechanisms 19 
result in age-related tendon deterioration. The results of this and previous studies (Thorpe et 20 
al., 2010) alternatively suggest that age-related alterations to the collagenous matrix may 21 
render the tendon matrix more resistant to degradation and remodelling, such that the cells 22 
are less able to repair areas of damage. This information will help guide the development of 23 
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Per mg tissue 
Corrected for 
DNA content 
p value  
Col1a2 34.93±7.23 19.42±4.30 0.85 
Col3a1 18.56±3.93 10.72±2.75 0.25 
Col5a1 1.49±0.40 0.84±0.22 0.36 
Col12a1 9.51±1.38 5.20±0.79 0.27 
Aggrecan 5.55±1.81 3.07±0.96 0.64 
Biglycan 63.27±13.76 35.84±8.44 0.63 
Decorin 1343.42±302.85 780.99±198.98 0.63 
Fibromodulin  32.80±6.68 18.53±3.90 0.51 
Lumican 48.50±7.45 27.62±5.30 0.98 
Tenascin 1.86±0.49 1.07±0.29 0.80 
Scleraxis 3.79±0.99 2.35±0.64 0.62 
COMP 2674.33±570.18 1516.06±320.36 0.61 
    
Table 1. Average gene expression of matrix proteins in the SDFT per tissue weight and corrected for 2 
DNA content. Data are displayed as Mean±SEM. Correlations are shown between horse age and 3 
mRNA levels corrected for DNA content. 4 












MMP-1 0.03±0.01 0.01±0.01 0.46 
MMP-3 3.52±0.83 1.89±0.45 0.054 
MMP-9 0.43±0.20 0.23±0.11 0.36 
MMP-10 17.46±4.48** 8.61±2.09** 0.0045 
MMP-13 0.16±0.12 0.07±0.05 0.76 
MMP-23 0.03±0.01 0.02±0.01 0.46 
TIMP-3 55.08±9.29 31.01±6.19 0.98 
TIMP-4 0.53±0.15 0.27±0.07 0.52 
ADAM-12 0.05±0.01 0.03±0.01 0.86 
ADAM-17 1.21±0.22 0.65±0.13 0.47 
ADAMTS-2 1.22±0.27 0.64±0.12 0.90 
Table 2. Average gene expression of matrix degrading enzymes in the SDFT per tissue weight and 1 
corrected for DNA content. Data are displayed as Mean±SEM. Correlations are shown between horse 2 
age and mRNA levels per cell. * indicates significant correlation with age. ** p>0.005. 3 
 4 
 5 
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Figure Legends 1 
Fig. 1 Tendon DNA content plotted as a function of horse age. 2 
Fig. 2 Gene expression levels of tendon extracellular matrix molecules as a function of horse 3 
age. There was no correlation between horse age and mRNA levels of Col1A2 (a), Col3A1 4 
(b), decorin (c), or biglycan (d). 5 
Fig. 3 Levels of the N-terminal propeptide of type I collagen (PINP) in SDFT tissue. PINP 6 
levels showed no relationship with horse age (a), and did not correlate with mRNA levels of 7 
Col1A2 (b). 8 
Fig. 4 Expression of matrix degrading enzymes as a function of horse age. MMP-3 mRNA 9 
levels did not show a significant relationship with horse age (a), but MMP-10 expression 10 
increased significantly with age (p=0.005). 11 
Fig. 5 Pro and active MMP-3 levels as a function of horse age measured using casein 12 
zymography. Both pro (;           ) and active (; --------) forms of MMP-3 increased 13 
significantly with horse age (a, p<0.02). There was a weak, but significant, correlation 14 
between total MMP-3 protein levels and MMP-3 mRNA levels (b, p=0.02). 15 
Fig. 6 Estimated relative telomere length plotted as a function of horse age. There was no 16 
correlation between horse age and relative telomere length. 17 
